Cancer Research Cancer Epigenetics Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirk, C. J.
Right arrow Articles by Mulé, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirk, C. J.
Right arrow Articles by Mulé, J. J.
[Cancer Research 61, 8794-8802, December 15, 2001]
© 2001 American Association for Cancer Research

Immunology

The Dynamics of the T-Cell Antitumor Response

Chemokine-secreting Dendritic Cells Can Prime Tumor-reactive T Cells Extranodally1

Christopher J. Kirk2, Dennis Hartigan-O’Connor and James J. Mulé3

Departments of Surgery [C. J. K., J. J. M.] and Internal Medicine [J. J. M.], Tumor Immunology and Immunotherapy Program of the Comprehensive Cancer Center [C. J. K., J. J. M.] and the Program in Cellular and Molecular Biology [D. H-O.], University of Michigan Medical Center, Ann Arbor, Michigan 48109-0666

Direct administration of dendritic cells (DCs) genetically modified to express secondary lymphoid tissue chemokine (SLC) into growing B16 melanoma could result in a substantial, sustained influx of T cells within the mass with only a transient increase in T-cell numbers in the draining lymph node (DLN). DCs were retained at the tumor site with only a very small percentage trafficking to the DLN. The T cells infiltrating the tumor mass expressed the activation marker CD25 within 24 h and developed IFN-{gamma}-secreting function within 7 days as tumor growth was inhibited. Similar results were obtained in lymphotoxin {alpha}-/- mice, which lacked peripheral lymph nodes. Our data demonstrate that effective T-cell priming can occur extranodally and result in measurable antitumor effects in vivo.




This article has been cited by other articles:


Home page
 JCOHome page
D. Coppola and J. J. Mule
Ectopic Lymph Nodes Within Human Solid Tumors
J. Clin. Oncol., September 20, 2008; 26(27): 4369 - 4370.
[Full Text] [PDF]

Home page
 JCOHome page
M.-C. Dieu-Nosjean, M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, N. Rabbe, L. Laurans, E. Tartour, L. de Chaisemartin, et al.
Long-Term Survival for Patients With Non-Small-Cell Lung Cancer With Intratumoral Lymphoid Structures
J. Clin. Oncol., September 20, 2008; 26(27): 4410 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
A. Grolleau-Julius, M. R. Garg, R. Mo, L. L. Stoolman, and R. L. Yung
Effect of Aging on Bone Marrow-Derived Murine CD11c+CD4-CD8{alpha}- Dendritic Cell Function.
J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2006; 61(10): 1039 - 1047.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. R. Ferrone, M.-A. Perales, S. M. Goldberg, C. J. Somberg, D. Hirschhorn-Cymerman, P. D. Gregor, M. J. Turk, T. Ramirez-Montagut, J. S. Gold, A. N. Houghton, et al.
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin fc domains.
Clin. Cancer Res., September 15, 2006; 12(18): 5511 - 5519.
[Abstract] [Full Text] [PDF]

Home page
 J BiochemHome page
L. Chun, C.-C. Yin, J.-Z. Song, M.-X. Liu, J.-H. Piao, Q. Lin, X.-B. Wang, and H.-L. Huang
Soluble Expression of Recombinant Human Secondary Lymphoid Chemokine (SLC) in E. coli and Research on Its In Vitro and In Vivo Bioactivity
J. Biochem., December 1, 2004; 136(6): 769 - 776.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. Lavergne, C. Combadiere, M. Iga, A. Boissonnas, O. Bonduelle, M. Maho, P. Debre, and B. Combadiere
Intratumoral CC Chemokine Ligand 5 Overexpression Delays Tumor Growth and Increases Tumor Cell Infiltration
J. Immunol., September 15, 2004; 173(6): 3755 - 3762.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-C. Yang, S. Hillinger, K. Riedl, L. Zhang, L. Zhu, M. Huang, K. Atianzar, B. Y. Kuo, B. Gardner, R. K. Batra, et al.
Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity
Clin. Cancer Res., April 15, 2004; 10(8): 2891 - 2901.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Guiducci, E. Di Carlo, M. Parenza, M. Hitt, M. Giovarelli, P. Musiani, and M. P. Colombo
Intralesional Injection of Adenovirus Encoding CC Chemokine Ligand 16 Inhibits Mammary Tumor Growth and Prevents Metastatic-Induced Death after Surgical Removal of the Treated Primary Tumor
J. Immunol., April 1, 2004; 172(7): 4026 - 4036.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Hillinger, S.-C. Yang, L. Zhu, M. Huang, R. Duckett, K. Atianzar, R. K. Batra, R. M. Strieter, S. M. Dubinett, and S. Sharma
EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-{gamma}-Dependent Antitumor Responses in a Lung Cancer Model
J. Immunol., December 15, 2003; 171(12): 6457 - 6465.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Grolleau, D. E. Misek, R. Kuick, S. Hanash, and J. J. Mule
Inducible Expression of Macrophage Receptor Marco by Dendritic Cells Following Phagocytic Uptake of Dead Cells Uncovered by Oligonucleotide Arrays
J. Immunol., September 15, 2003; 171(6): 2879 - 2888.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
X. Lin, X. Ma, M. Rodriguez, X. Feng, L. Zoecklein, Y.-X. Fu, and R. P. Roos
Membrane lymphotoxin is required for resistance to Theiler's virus infection
Int. Immunol., August 1, 2003; 15(8): 955 - 962.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. J. Kobie, R. S. Wu, R. A. Kurt, S. Lou, M. K. Adelman, L. J. Whitesell, L. V. Ramanathapuram, C. L. Arteaga, and E. T. Akporiaye
Transforming Growth Factor {beta} Inhibits the Antigen-Presenting Functions and Antitumor Activity of Dendritic Cell Vaccines
Cancer Res., April 15, 2003; 63(8): 1860 - 1864.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.